Natera
NTRA
Performance
About Natera
Natera is a global leader in molecular diagnostics focused on cell-free DNA testing for oncology, women’s health, and organ health. The company develops cfDNA-based tests to inform personalized care decisions, including tumor profiling, hereditary cancer screening, and transplant assessments, with laboratories that are CAP/CLIA-certified and ISO 13485 certified. Its offerings span across oncology, prenatal and pregnancy genetics, and organ health, serving patients and clinicians worldwide. Natera emphasizes integrating test information into healthcare decisions and highlights extensive clinical validation and millions of patient studies in its portfolio.
Recent News
Early ALPHA3 Data Could Signal Shift to Frontline Use of CAR T in LBCL
Here Are Tuesday's Biggest Analyst Calls: Apple, Tesla, Amazon, GM, Crocs, Viking, Alphabet, Ford & More
Assessing the Roche Acquisition of SAGA Diagnostics and the Future of Molecular Residual Disease Monitoring
FDA Clears Genentech’s Tecentriq for ctDNA-Guided Adjuvant Bladder Cancer Therapy
I Saved $800 on My Medical Bills With a Little-Known Trick. You Can Do It Too.
Natera’s Solomon Moshkevich on How MRD Testing Pinpoints Cancer Recurrence
FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease
Citi Flags 16 Stocks to Buy that Are Primed to Pop After Q1 Earnings
In the Clinic for April 1, 2026
Quinn Emanuel Just Got a $3 Million Ethics Lesson. A Judge Made Them Write It Themselves.
Lee Ainslie Portfolio Analysis: Key Positions, AI Bets & Maverick Capital Strategy
Genentech Reports FDA Approval of Tecentriq and Tecentriq Hybreza for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
FDA Grants First ctDNA-Guided Approval for Genentech's Tecentriq in Bladder Cancer